A5080161292- Amyloidosis: Diagnosis, Treatment, Outcomes
- Multiple Myeloma Research and Treatments
- Chronic Myeloid Leukemia Treatments
- Peptidase Inhibition and Analysis
- Chronic Lymphocytic Leukemia Research
- Parathyroid Disorders and Treatments
- Protein Degradation and Inhibitors
- Immune cells in cancer
- Galectins and Cancer Biology
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Platelet Disorders and Treatments
- Glycosylation and Glycoproteins Research
- Lymphoma Diagnosis and Treatment
- Protein Kinase Regulation and GTPase Signaling
- Neuroendocrine Tumor Research Advances
- Alcohol Consumption and Health Effects
- HIV/AIDS drug development and treatment
- Sarcoidosis and Beryllium Toxicity Research
- IgG4-Related and Inflammatory Diseases
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Angiogenesis and VEGF in Cancer
- Cell Adhesion Molecules Research
- Cardiac electrophysiology and arrhythmias
Istituti di Ricovero e Cura a Carattere Scientifico
2022-2025
University of Pavia
2022-2025
Policlinico San Matteo Fondazione
2024-2025
Ospedale Garibaldi
2023-2024
Azienda di Rilievo Nazionale ed Alta Specializzazione
2023
Policlinico Universitario di Catania
2021-2022
University of Catania
2021-2022
Azienda Ospedaliero-Universitaria Policlinico - Vittorio Emanuele
2019-2021
Abstract To understand neutrophil impairment in the progression from MGUS through active MM, we investigated function of mature, high-density neutrophils (HDNs), isolated peripheral blood. In 7 3 and healthy subjects by gene expression profile, identified a total 551 upregulated 343 downregulated genes MM-HDN, involved chemokine signaling pathway FC-gamma receptor mediated phagocytosis conveying activation STAT proteins. series 60 newly diagnosed MM 30 patients, flow-cytometry found that HDN...
Key Points Patients with AA amyloidosis and age ≥65 years, eGFR <45 ml/min per 1.73 m 2 , N -terminal type-B natriuretic peptide >1000 ng/L and/or >130 at diagnosis have poorer survival. Proteinuria >3.0 g/24 hours <35 identify patients high risk of progression to end-stage kidney failure. Prognostic stratification in can be easily made by staging systems, similarly AL transthyretin amyloidosis. Background The is involved almost 100% cases amyloidosis, a rare disease caused...
In both monoclonal gammopathy of uncertain significance (MGUS) and multiple myeloma (MM) patients, immune functions are variably impaired, there is a high risk bacterial infections. Neutrophils the most abundant circulating leukocytes constitute first line host defense. Since little known about contribution autophagy in neutrophil function MGUS MM we investigated basal flux freshly sorted neutrophils patients tested plastic response healthy to soluble factors MM. high-density obtained from...
Based on the results obtained in clinical trials, use of combination lenalidomide and dexamethasone (Len/Dex) has become a potential therapeutic choice for newly diagnosed multiple myeloma (NDMM) ineligible autologous stem cell transplantation. This study evaluated 89 frail NDMM patients treated with first-line oral association. At last follow-up, 34 out (38.2%) were alive, 22 still treatment Len/Dex. Among 73 evaluable who received at least two cycles, overall response rate was 71% (N =...
Background The anti-CD38 monoclonal antibody daratumumab is approved as a single agent for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) who received at least three prior lines therapy, including proteasome inhibitor and immunomodulatory agent. A retrospective multicentric study was designed to evaluate feasibility, tolerability, efficacy in monotherapy RRMM. Methods This included 44 consecutive RRMM that underwent after median number four therapies (range 2–9)....
Background Early identification of immunoglobulin light-chain amyloidosis (AL) is crucial due to its rapid progression. Monoclonal (M-LC) testing the first step in diagnostic workup for patients with suspected cardiac (CA). We aimed determine whether time interval between CA suspicion and M-LC can be related AL survival outcomes.
In the era of novel drugs a growing number multiple myeloma (MM) patients are treated until disease progression. Serum free light chain (sFLC) assay is recommended for monitoring in oligo-secretory and micromolecular MM. this real-life survey, total 130 relapsed/refractory MM at our center with least three lines were investigated as retrospective cohort. The median age diagnosis was 64 years more than half male. A 24 (18%) had oligo-secretory/micromolecular diagnosis. More 20% 106...
Abstract Daratumumab‐based regimens are the new standard of care for newly diagnosed patients with AL amyloidosis based on results ANDROMEDA study. However, real‐world data daratumumab efficacy in upfront therapy unselected scanty. In framework a prospective observational study, we investigated and safety 88 patients, including subjects IIIb cardiac stage (26%) or myeloma defining events (29%). Daratumumab was administered bortezomib 50 (56%) lenalidomide 31 (35%), monotherapy 7 (8%). The...